CN106102740A - 治疗先天性肾上腺增生的crf1受体拮抗剂 - Google Patents

治疗先天性肾上腺增生的crf1受体拮抗剂 Download PDF

Info

Publication number
CN106102740A
CN106102740A CN201580005270.4A CN201580005270A CN106102740A CN 106102740 A CN106102740 A CN 106102740A CN 201580005270 A CN201580005270 A CN 201580005270A CN 106102740 A CN106102740 A CN 106102740A
Authority
CN
China
Prior art keywords
crf
receptor antagonist
acth
nbi
cah
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580005270.4A
Other languages
English (en)
Chinese (zh)
Inventor
季米特·E·格里戈里尔蒂斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Biosciences Inc
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52450623&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN106102740(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Priority to CN202010134003.XA priority Critical patent/CN111228274A/zh
Publication of CN106102740A publication Critical patent/CN106102740A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201580005270.4A 2014-01-21 2015-01-21 治疗先天性肾上腺增生的crf1受体拮抗剂 Pending CN106102740A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010134003.XA CN111228274A (zh) 2014-01-21 2015-01-21 治疗先天性肾上腺增生的crf1受体拮抗剂

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461929941P 2014-01-21 2014-01-21
US61/929,941 2014-01-21
US201461981033P 2014-04-17 2014-04-17
US61/981,033 2014-04-17
US201462069155P 2014-10-27 2014-10-27
US62/069,155 2014-10-27
PCT/US2015/012315 WO2015112642A1 (en) 2014-01-21 2015-01-21 Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010134003.XA Division CN111228274A (zh) 2014-01-21 2015-01-21 治疗先天性肾上腺增生的crf1受体拮抗剂

Publications (1)

Publication Number Publication Date
CN106102740A true CN106102740A (zh) 2016-11-09

Family

ID=52450623

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580005270.4A Pending CN106102740A (zh) 2014-01-21 2015-01-21 治疗先天性肾上腺增生的crf1受体拮抗剂
CN202010134003.XA Pending CN111228274A (zh) 2014-01-21 2015-01-21 治疗先天性肾上腺增生的crf1受体拮抗剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010134003.XA Pending CN111228274A (zh) 2014-01-21 2015-01-21 治疗先天性肾上腺增生的crf1受体拮抗剂

Country Status (24)

Country Link
US (5) US20170020877A1 (enExample)
EP (2) EP4450070A1 (enExample)
JP (5) JP6585625B2 (enExample)
KR (2) KR20210064407A (enExample)
CN (2) CN106102740A (enExample)
AU (4) AU2015209452C1 (enExample)
BR (1) BR112016016975B1 (enExample)
CA (2) CA3155599A1 (enExample)
DK (1) DK3096756T3 (enExample)
ES (1) ES2984706T3 (enExample)
FI (1) FI3096756T3 (enExample)
HR (1) HRP20241046T1 (enExample)
HU (1) HUE068315T2 (enExample)
IL (5) IL317035A (enExample)
LT (1) LT3096756T (enExample)
MX (3) MX389004B (enExample)
NZ (1) NZ722122A (enExample)
PL (1) PL3096756T3 (enExample)
PT (1) PT3096756T (enExample)
RS (1) RS65839B1 (enExample)
RU (1) RU2718918C2 (enExample)
SI (1) SI3096756T1 (enExample)
SM (1) SMT202400361T1 (enExample)
WO (1) WO2015112642A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112423747A (zh) * 2018-04-27 2021-02-26 云杉生物科学公司 用于治疗睾丸肾上腺残余瘤和卵巢肾上腺残余瘤的方法
CN113518616A (zh) * 2018-12-07 2021-10-19 纽罗克里生物科学有限公司 用于治疗先天性肾上腺皮质增生症的crf1受体拮抗剂、其药物制剂和固体形式
CN114502162A (zh) * 2019-09-27 2022-05-13 纽罗克里生物科学有限公司 Crf受体拮抗剂及使用方法
CN116322544A (zh) * 2020-08-12 2023-06-23 云杉生物科学公司 用于治疗多囊卵巢综合征的方法和组合物
US11951112B2 (en) 2021-04-12 2024-04-09 Maxim Masiutin Method of treating late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency by individually tailored glucocorticoid regimen

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106102740A (zh) 2014-01-21 2016-11-09 纽罗克里生物科学有限公司 治疗先天性肾上腺增生的crf1受体拮抗剂
CA2940242A1 (en) 2014-02-20 2015-08-27 Alder Biopharmaceuticals, Inc. Anti-acth antibodies and use thereof
US11077108B2 (en) 2016-09-07 2021-08-03 The Regents Of The University Of California Allosteric corticotropin-releasing factor receptor 1 (CRFR1) antagonists that decrease p-tau and improve cognition
WO2019036503A1 (en) * 2017-08-14 2019-02-21 Spruce Biosciences, Inc. CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS
JP7532328B2 (ja) * 2018-12-07 2024-08-13 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 先天性副腎過形成を処置するためのｃｒｆ１受容体アンタゴニスト、その医薬製剤および固体形態
JP2022541550A (ja) * 2019-07-19 2022-09-26 スプルース バイオサイエンシーズ，インク． 先天性副腎過形成を処置する方法
CA3181084A1 (en) * 2020-06-10 2021-12-16 Robert H. FARBER Crf1 receptor antagonist for the treatment of congenital adrenal hyperplasia
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013160315A2 (en) * 2012-04-23 2013-10-31 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Genetic predictors of response to treatment with crhr1 antagonists

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4949582B1 (enExample) 1969-01-20 1974-12-27
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
FR2692893B1 (fr) 1992-06-24 1994-09-02 Sanofi Elf Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
US6664261B2 (en) 1996-02-07 2003-12-16 Neurocrine Biosciences, Inc. Pyrazolopyrimidines as CRF receptor antagonists
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
ATE213495T1 (de) 1996-09-16 2002-03-15 Du Pont Pharm Co Eine resorbierbare röntgenopake markierung enthaltendes chirurgisches implantat und verfahren zum verriegeln desselben in einem körper
FR2754258B1 (fr) 1996-10-08 1998-12-31 Sanofi Sa Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
CA2272291C (en) 1997-04-22 2008-06-17 Janssen Pharmaceutica N.V. Crf antagonistic quino- and quinazolines
EP0937081A1 (en) 1997-08-22 1999-08-25 Du Pont Pharmaceuticals Company NITROGEN SUBSTITUTED IMIDAZO 4,5-c]PYRAZOLES AS CORTICOTROPIN RELEASING HORMONE ANTAGONISTS
US6531475B1 (en) 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
CA2369553A1 (en) 1999-04-02 2000-10-12 Raymond F. Horvath N-benzimidazolylmethyl and n-indolylmethyl-benzamides and their use as crf modulators
FR2796380B3 (fr) 1999-07-15 2001-08-17 Sanofi Synthelabo Nouveaux derives d'aminothiazoles, leur preparation et les compositions pharmaceutiques les contenant
FR2802530B1 (fr) 1999-12-17 2002-02-22 Sanofi Synthelabo Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2,4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant
WO2003006015A1 (en) 2001-07-13 2003-01-23 Bristol-Myers Squibb Pharma Company Substituted thiazoles and oxazoles as corticotropin releasing hormone ligands
WO2005079807A1 (en) 2004-02-13 2005-09-01 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
JP2008509933A (ja) 2004-08-13 2008-04-03 エミスフェアー・テクノロジーズ・インク 送達剤のマイクロ粒子またはナノ粒子を含む医薬製剤
ATE430746T1 (de) 2004-10-19 2009-05-15 Smithkline Beecham Cork Ltd Crf-rezeptor-antagonisten und zugehörige verfahren
GB0519957D0 (en) 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
DK1869049T3 (da) 2005-03-21 2009-05-18 Lilly Co Eli Imidazopyridazinforbindelser
EP1879896A1 (en) 2005-04-05 2008-01-23 Eli Lilly And Company Imidazopyridazine compounds
TWI370820B (en) 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
US20090234117A1 (en) 2005-05-27 2009-09-17 Toshihiko Kashiwagi Pyrazolopyrimidine Derivative
US8828392B2 (en) 2005-11-10 2014-09-09 Topotarget Uk Limited Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent
WO2007069565A1 (ja) 2005-12-12 2007-06-21 Ono Pharmaceutical Co., Ltd. 二環式複素環化合物
EP1961754A4 (en) 2005-12-15 2009-11-11 Ono Pharmaceutical Co BICYCLIC HETEROCYCLIC COMPOUND
US8153127B2 (en) 2006-02-07 2012-04-10 Phenoquest Ag Method of treating depression
EP1834641A1 (en) 2006-03-16 2007-09-19 Sanofi-Aventis Use of CRF1 receptor antagonists for preparing a drug for treating metabolic syndrome and/or obesity and/or dyslipoproteinemia
EP2029136A4 (en) 2006-05-22 2010-01-06 Vanda Pharmaceuticals Inc TREATMENT FOR DEPRESSION DISEASES
ES2428543T3 (es) 2006-09-20 2013-11-08 Eli Lilly And Company Compuestos de tiofenopirazolopirimidina
KR101088239B1 (ko) * 2006-09-20 2011-11-30 일라이 릴리 앤드 캄파니 Ｃｒｆ１ 수용체 길항제로서의 티아졸 피라졸로피리미딘
WO2008051533A2 (en) 2006-10-25 2008-05-02 Takeda Pharmaceutical Company Limited Benzimidazole compounds
WO2008083070A1 (en) 2006-12-29 2008-07-10 Neurogen Corporation Crf1 receptor ligands comprising fused bicyclic heteroaryl moieties
JP2010514672A (ja) 2006-12-29 2010-05-06 武田薬品工業株式会社 Ｃｒｆアンタゴニスト活性を有する縮合複素環化合物
TW200902019A (en) 2007-04-26 2009-01-16 Ono Pharmaceutical Co Dicyclic heterocyclic compound
WO2009008552A1 (en) 2007-07-11 2009-01-15 Taisho Pharmaceutical Co., Ltd. 8-aryl-4-alkylpyrrolo[2,3,4-de]quinolin-5(4h)-one and 8-aryl-4-alkyl-4,5-dihydropyrrolo[2,3,4-de]quinolin-5-ol derivatives
WO2009144632A1 (en) 2008-05-30 2009-12-03 Pfizer Limited Novel compounds
CN102105149A (zh) 2008-07-31 2011-06-22 百时美施贵宝公司 作为促肾上腺皮质激素释放因子受体活性调节剂的取代的氨基甲酸酯衍生物
US7932256B2 (en) 2008-07-31 2011-04-26 Bristol-Myers Squibb Company (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity
US7994203B2 (en) 2008-08-06 2011-08-09 Novartis Ag Organic compounds
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
US8974500B2 (en) 2008-11-03 2015-03-10 DePuy Synthes Products, LLC Adjustable rod assembly
US8551996B2 (en) 2009-02-20 2013-10-08 Emory University Compounds, compositions, methods of synthesis, and methods of treatment
HUP0900267A2 (en) 2009-04-30 2011-03-28 Sanofi Aventis Process for preparing of thiazole amines and intermediates thereof
JPWO2011043387A1 (ja) 2009-10-08 2013-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロオキサゾール化合物
AR078521A1 (es) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531510B1 (en) 2010-02-01 2014-07-23 Novartis AG Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
EP4140487A1 (en) 2012-04-13 2023-03-01 Epizyme Inc Combination therapy for treating cancer
JP2015516979A (ja) 2012-04-23 2015-06-18 ホルスボールマッシュマイヤー ニューロケミー ゲーエムベーハーＨｏｌｓｂｏｅｒｍａｓｃｈｍｅｙｅｒ Ｎｅｕｒｏｃｈｅｍｉｅ Ｇｍｂｈ Ｃｒｈ過剰活性を有する患者の治療に用いるためのｃｒｈｒ１アンタゴニスト
CN106102740A (zh) 2014-01-21 2016-11-09 纽罗克里生物科学有限公司 治疗先天性肾上腺增生的crf1受体拮抗剂
WO2016065177A1 (en) 2014-10-22 2016-04-28 The Trustees Of The University Of Pennsylvania Method of treating depression and other stress related disorders
CN107438606B (zh) 2015-02-06 2020-09-18 纽罗克里生物科学有限公司 [9,10-二甲氧基-3-(2-甲基丙基)-1h,2h,3h,4h,6h,7h,11bh-吡啶并-[2,1-a]异喹啉-2-基]甲醇及与其相关的化合物、组合物和方法
EP3277836B1 (en) 2015-04-02 2019-02-27 HMNC Value GmbH Method of treatment using genetic predictors of a response to treatment with ssr-125543
KR102372032B1 (ko) * 2016-07-14 2022-03-08 가부시키가이샤 코나미 데지타루 엔타테인멘토 게임 시스템, 단말 장치 및 프로그램
JP7595413B2 (ja) 2016-11-30 2024-12-06 ケース ウエスタン リザーブ ユニバーシティ １５－ｐｇｄｈ阻害剤とコルチコステロイドおよび／またはｔｎｆ阻害剤との組み合わせならびにその使用
WO2018219804A1 (en) 2017-06-02 2018-12-06 Bayer Pharma Aktiengesellschaft Self-microemulsifying drug delivery systems
CA3064445A1 (en) 2017-08-14 2019-02-21 Spruce Biosciences, Inc. Corticotropin releasing factor receptor antagonists
WO2019036503A1 (en) 2017-08-14 2019-02-21 Spruce Biosciences, Inc. CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS
EP3784233B1 (en) * 2018-04-27 2024-06-05 Spruce Biosciences, Inc. Methods for treating testicular and ovarian adrenal rest tumors
EP3984523B1 (en) 2018-12-07 2025-09-03 Neurocrine Biosciences, Inc. Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
JP2022541550A (ja) 2019-07-19 2022-09-26 スプルース バイオサイエンシーズ，インク． 先天性副腎過形成を処置する方法
WO2021062246A1 (en) 2019-09-27 2021-04-01 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
AR120649A1 (es) 2019-12-04 2022-03-09 Neurocrine Biosciences Inc Antagonistas del receptor de crf y métodos de uso
CA3181084A1 (en) 2020-06-10 2021-12-16 Robert H. FARBER Crf1 receptor antagonist for the treatment of congenital adrenal hyperplasia
WO2022046905A1 (en) 2020-08-26 2022-03-03 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013160315A2 (en) * 2012-04-23 2013-10-31 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Genetic predictors of response to treatment with crhr1 antagonists

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DOLLE FREDERIC等: "Radiosynthesis of [C-11]SSR126374, a new selective CRF1 antagonist", 《JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS》 *
E ZOUMAKIS等: "Corticotropin-releasing hormone receptor antagonists", 《EUROPEAN JOURNAL OF ENDOCRINOLOGY》 *
FREDERICK BARREAU等: "Pathways involved in gut mucosal barrier dysfunction induced in adult rats by maternal deprivation: corticotrophin-releasing factor and nerve growth factor interplay", 《JOURNAL OF PHYSIOLOGY-LONDON》 *
FREDERICK BARREAU等: "Pathways involved in gut mucosal barrier dysfunction induced in adult rats by maternal deprivation：corticotrophin-releasing factor and nerve growth factor interplay", 《JOURNAL OF PHYSIOLOGY-LONDON》 *
KAREN J. LOECHNER等: "Alternative Strategies for the Treatment of Classical Congenital Adrenal Hyperplasia: Pitfalls and Promises", 《INTERNATIONAL JOURNAL OF PEDIATRIC ENDOCRINOLOGY》 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112423747A (zh) * 2018-04-27 2021-02-26 云杉生物科学公司 用于治疗睾丸肾上腺残余瘤和卵巢肾上腺残余瘤的方法
CN113518616A (zh) * 2018-12-07 2021-10-19 纽罗克里生物科学有限公司 用于治疗先天性肾上腺皮质增生症的crf1受体拮抗剂、其药物制剂和固体形式
CN116322668A (zh) * 2018-12-07 2023-06-23 纽罗克里生物科学有限公司 用于制备4-(2-氯-4-甲氧基-5-甲基苯基)-n-[(1s)-2-环丙基-1-(3-氟-4-甲基苯基)乙基]-5-甲基-n-丙-2-炔基-1,3-噻唑-2-胺的合成方法
US12128033B2 (en) 2018-12-07 2024-10-29 Neurocrine Biosciences, Inc. Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine
CN113518616B (zh) * 2018-12-07 2025-10-14 纽罗克里生物科学有限公司 用于治疗先天性肾上腺皮质增生症的crf1受体拮抗剂、其药物制剂和固体形式
CN114502162A (zh) * 2019-09-27 2022-05-13 纽罗克里生物科学有限公司 Crf受体拮抗剂及使用方法
CN114502162B (zh) * 2019-09-27 2025-03-28 纽罗克里生物科学有限公司 Crf受体拮抗剂及使用方法
US12383536B2 (en) 2019-09-27 2025-08-12 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods of use
CN116322544A (zh) * 2020-08-12 2023-06-23 云杉生物科学公司 用于治疗多囊卵巢综合征的方法和组合物
CN116322544B (zh) * 2020-08-12 2024-08-02 云杉生物科学公司 用于治疗多囊卵巢综合征的方法和组合物
US12098152B2 (en) 2020-08-12 2024-09-24 Spruce Biosciences, Inc. Methods and compositions for treating polycystic ovary syndrome
US11951112B2 (en) 2021-04-12 2024-04-09 Maxim Masiutin Method of treating late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency by individually tailored glucocorticoid regimen

Also Published As

Publication number Publication date
JP2017503030A (ja) 2017-01-26
US20240058342A1 (en) 2024-02-22
WO2015112642A1 (en) 2015-07-30
CA2936974A1 (en) 2015-07-30
KR20210064407A (ko) 2021-06-02
MX389004B (es) 2025-03-20
ES2984706T3 (es) 2024-10-30
IL246783B (en) 2021-10-31
JP6585625B2 (ja) 2019-10-02
EP4450070A1 (en) 2024-10-23
JP7104743B2 (ja) 2022-07-21
AU2015209452B2 (en) 2020-05-07
AU2024219813A1 (en) 2024-10-10
AU2020207774B2 (en) 2022-08-04
MX2022000080A (es) 2022-02-03
IL304134B2 (en) 2025-04-01
RU2020112197A (ru) 2020-05-21
US10905690B2 (en) 2021-02-02
US20170020877A1 (en) 2017-01-26
EP3096756A1 (en) 2016-11-30
IL317035A (en) 2025-01-01
SI3096756T1 (sl) 2024-09-30
CN111228274A (zh) 2020-06-05
JP6936825B2 (ja) 2021-09-22
BR112016016975B1 (pt) 2022-12-27
JP2022010260A (ja) 2022-01-14
AU2015209452A1 (en) 2016-08-04
CA3155599A1 (en) 2015-07-30
MX2021012539A (es) 2021-11-12
RU2718918C2 (ru) 2020-04-15
IL304134B1 (en) 2024-12-01
JP2020138978A (ja) 2020-09-03
AU2022263460B2 (en) 2024-10-17
US20210361659A1 (en) 2021-11-25
JP2019081814A (ja) 2019-05-30
IL296683A (en) 2022-11-01
RS65839B1 (sr) 2024-09-30
LT3096756T (lt) 2024-08-26
US11311544B2 (en) 2022-04-26
US11730739B2 (en) 2023-08-22
NZ722122A (en) 2020-06-26
IL304134A (en) 2023-09-01
BR112016016975A2 (pt) 2017-08-08
KR102258522B1 (ko) 2021-05-31
JP2024098001A (ja) 2024-07-19
MX2016009499A (es) 2017-02-27
SMT202400361T1 (it) 2024-11-15
RU2016133972A3 (enExample) 2018-09-26
IL286782A (en) 2021-10-31
EP3096756B1 (en) 2024-06-12
FI3096756T3 (fi) 2024-08-14
PT3096756T (pt) 2024-08-26
AU2022263460A1 (en) 2022-12-08
IL246783A0 (en) 2016-08-31
AU2020207774A1 (en) 2020-08-06
DK3096756T3 (da) 2024-08-05
HRP20241046T1 (hr) 2024-11-08
IL296683B2 (en) 2023-12-01
AU2015209452C1 (en) 2020-11-05
US20210137926A1 (en) 2021-05-13
KR20160106176A (ko) 2016-09-09
US20190231781A1 (en) 2019-08-01
HUE068315T2 (hu) 2024-12-28
PL3096756T3 (pl) 2024-10-28
RU2016133972A (ru) 2018-03-05
IL296683B1 (en) 2023-08-01

Similar Documents

Publication Publication Date Title
US11311544B2 (en) Treatment of congenital adrenal hyperplasia
WO2021016208A1 (en) Methods of treating congenital adrenal hyperplasia
HK40116454A (en) Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
RU2812318C2 (ru) Антагонисты рецептора cfr1 для лечения врожденной гиперплазии коры надпочечников
HK40030956A (en) Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
HK1231749B (en) Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
HK1231749A1 (en) Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20161109

RJ01 Rejection of invention patent application after publication